15 Feb 2018 14:27
Additional listing
15 February 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 30,000 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 21 February 2018. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of shares in issue, following admission, will be 70,021,624. The Company holds no shares in Treasury.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
|
|
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: Optimum Strategic Communications Mary Clark/ Eva Haas/ Hollie Vile silence@optimumcomms.com
| Tel: +44 (0) 20 3714 1788 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
SLN.L (SLN)